Moderna, Inc. (NASDAQ:MRNA) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC cut its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 35.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 71,395 shares of the company's stock after selling 38,366 shares during the quarter. SG Americas Securities LLC's holdings in Moderna were worth $2,024,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Sentry Investment Management LLC purchased a new stake in shares of Moderna in the first quarter valued at about $31,000. Compass Planning Associates Inc purchased a new stake in shares of Moderna in the fourth quarter valued at approximately $37,000. Venturi Wealth Management LLC raised its position in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after acquiring an additional 664 shares in the last quarter. Crowley Wealth Management Inc. purchased a new stake in shares of Moderna during the 4th quarter worth $41,000. Finally, Itau Unibanco Holding S.A. grew its stake in shares of Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after purchasing an additional 343 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Down 2.5%

Shares of NASDAQ:MRNA opened at $26.67 on Monday. The firm has a market cap of $10.31 billion, a price-to-earnings ratio of -2.87 and a beta of 1.86. The stock's 50-day moving average price is $26.29 and its two-hundred day moving average price is $32.91. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $139.92.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business had revenue of $108.00 million for the quarter, compared to analysts' expectations of $130.35 million. During the same period last year, the company earned ($3.07) earnings per share. The company's quarterly revenue was down 35.3% on a year-over-year basis. As a group, research analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MRNA has been the topic of several recent analyst reports. Royal Bank of Canada lowered their target price on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. Evercore ISI decreased their target price on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. JPMorgan Chase & Co. dropped their price target on Moderna from $33.00 to $26.00 and set an "underweight" rating for the company in a research report on Thursday, May 22nd. Finally, Barclays cut their target price on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $46.61.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.